Literature DB >> 15012652

The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study.

.   

Abstract

OBJECTIVES: This paper describes the development of the UK Collaborative HIV Cohort (CHIC) Study. The aim of the study is to collate routinely collected data on HIV-infected individuals attending one of seven clinical centres in the UK since 1 January 1996, with the objectives of describing changes over time in the frequency of AIDS-defining illnesses, describing the uptake of and response to highly active antiretroviral therapy (HAART), and identifying factors associated with virological and immunological responses to HAART.
METHODS: By December 2002, demographic, clinical and laboratory data had been collected on HIV-positive patients seen at six of the seven HIV centres. Missing and inconsistent data had been investigated and the datasets audited. Records identified as relating to the same patient had been merged, and cross-checks made with UK death registers to improve the accuracy of death reporting.
RESULTS: The cohort currently contains information on 13,833 individuals. Eighty-two per cent of the cohort are male, and the median age was 34 years at first follow-up. The main risk factors for HIV infection have been determined as sex between men (63%) and sex between men and women (24%). Twenty-five per cent of the cohort are known to have developed AIDS, and 8% have died.
CONCLUSIONS: The UK CHIC Study provides important information on the status of individuals infected with HIV in the UK, and provides a means to study the response to HAART and to monitor changes in the clinical event and death rates that have occurred since the introduction of HAART in the UK.

Entities:  

Mesh:

Year:  2004        PMID: 15012652     DOI: 10.1111/j.1468-1293.2004.00197.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  57 in total

1.  National characteristics and trends in antiretroviral treatment in Australia can be accurately estimated using a large clinical cohort.

Authors:  Robin Huang; Kathy Petoumenos; Richard T Gray; Hamish McManus; Nila Dharan; Rebecca Guy; David A Cooper
Journal:  J Clin Epidemiol       Date:  2018-04-25       Impact factor: 6.437

2.  Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.

Authors:  Caroline A Sabin; Teresa Hill; Fiona Lampe; Ryanne Matthias; Sanjay Bhagani; Richard Gilson; Mike S Youle; Margaret A Johnson; Martin Fisher; George Scullard; Philippa Easterbrook; Brian Gazzard; Andrew N Phillips
Journal:  BMJ       Date:  2005-03-04

3.  Recent and Rapid Transmission of HIV Among People Who Inject Drugs in Scotland Revealed Through Phylogenetic Analysis.

Authors:  Manon Ragonnet-Cronin; Celia Jackson; Amanda Bradley-Stewart; Celia Aitken; Andrew McAuley; Norah Palmateer; Rory Gunson; David Goldberg; Catriona Milosevic; Andrew J Leigh Brown
Journal:  J Infect Dis       Date:  2018-05-25       Impact factor: 5.226

4.  The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

Authors:  Maile Ray; Roger Logan; Jonathan A C Sterne; Sonia Hernández-Díaz; James M Robins; Caroline Sabin; Loveleen Bansi; Ard van Sighem; Frank de Wolf; Dominique Costagliola; Emilie Lanoy; Heiner C Bucher; Viktor von Wyl; Anna Esteve; Jordi Casbona; Julia del Amo; Santiago Moreno; Amy Justice; Joseph Goulet; Sara Lodi; Andrew Phillips; Rémonie Seng; Laurence Meyer; Santiago Pérez-Hoyos; Patricia García de Olalla; Miguel A Hernán
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

5.  Measuring the Quality of Data Collection in a Large Observational Cohort of HIV and AIDS.

Authors:  Mariska Hillebregt; Elly de Lange-de Klerk; Dirk Knol; Frank de Wolf; Colette Smit
Journal:  Open AIDS J       Date:  2010-05-05

6.  Factors influencing lopinavir and atazanavir plasma concentration.

Authors:  Wolfgang Stöhr; David Back; David Dunn; Caroline Sabin; Alan Winston; Richard Gilson; Deenan Pillay; Teresa Hill; Jonathan Ainsworth; Brian Gazzard; Clifford Leen; Loveleen Bansi; Martin Fisher; Chloe Orkin; Jane Anderson; Margaret Johnson; Philippa Easterbrook; Sara Gibbons; Saye Khoo
Journal:  J Antimicrob Chemother       Date:  2010-01       Impact factor: 5.790

7.  Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studies.

Authors:  Bryan Lau; Stephen J Gange; Gregory D Kirk; Richard D Moore
Journal:  Epidemiology       Date:  2009-09       Impact factor: 4.822

8.  CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.

Authors:  Mark Bower; Martin Fisher; Teresa Hill; Iain Reeves; John Walsh; Chloe Orkin; Andrew N Phillips; Loveleen Bansi; Richard Gilson; Philippa Easterbrook; Margaret Johnson; Brian Gazzard; Clifford Leen; Deenan Pillay; Achim Schwenk; Jane Anderson; Kholoud Porter; Mark Gompels; Caroline A Sabin
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

9.  Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom.

Authors:  Gareth J Hughes; Esther Fearnhill; David Dunn; Samantha J Lycett; Andrew Rambaut; Andrew J Leigh Brown
Journal:  PLoS Pathog       Date:  2009-09-25       Impact factor: 6.823

10.  Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care.

Authors:  Susie E Huntington; Claire Thorne; Loveleen K Bansi; Jane Anderson; Marie-Louise Newell; Graham P Taylor; Deenan Pillay; Teresa Hill; Pat A Tookey; Caroline A Sabin
Journal:  AIDS       Date:  2013-01-02       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.